Bulk Pharmaceutical API Sources for NYDRAZID

Bulk Pharmaceutical API Sources for NYDRAZID

Vendor	Vendor Homepage	Vendor Sku	API Url
Vitas-M Laboratory		STK086288
TCI (Tokyo Chemical Industry)		I0138
Molport		MolPort-000-141-557
AKos Consulting & Solutions		AKOS000119062
TimTec		ST078858
Vitas-M Laboratory		BBL008409

Bulk Active Pharmaceutical Ingredient (API) Sources for NYDRAZID: A Strategic Overview

Last updated: August 9, 2025

---

Introduction

Nydrazid, the proprietary and brand name for Para-aminosalicylic acid (PAS), is an established second-line antibiotic used primarily in the treatment of tuberculosis, particularly multidrug-resistant strains. As a critical component in tuberculosis regimens, sourcing high-quality, reliable bulk APIs is vital for pharmaceutical companies, wholesalers, and compounding entities. This detailed analysis evaluates the current landscape and strategic considerations for sourcing bulk API supplies for Nydrazid, emphasizing global production hubs, quality assurance, and supply chain resilience.

---

Market Overview and Importance of API Sourcing for Nydrazid

Nydrazid's Role in TB Therapy:
Nydrazid is a synthetic analog of salicylic acid, exhibiting bacteriostatic effects against Mycobacterium tuberculosis. Its utilization is pivotal in combination therapies, particularly where first-line drugs like isoniazid and rifampicin fail due to resistance. The limited number of manufacturers specializing in PAS underscores the necessity for sourcing strategies that ensure consistent supply and compliance with pharmacopeial standards.

Demand Dynamics:
The persistent global burden of tuberculosis, especially in regions with high multidrug-resistant TB (MDR-TB) prevalence, sustains steady demand for Nydrazid. The World Health Organization estimates approximately 10 million new TB cases annually ([1]), reinforcing the essential role of bulk API suppliers in global health initiatives.

---

Global API Manufacturing Landscape for Nydrazid

1. Primary Manufacturing Hubs

• India:
  India dominates the production of generic APIs, including PAS. The country hosts numerous WHO-GMP certified manufacturers capable of scaling APIs for global distribution. Companies such as BASF, Glenmark, Sun Pharma, and regional players produce PAS in bulk, leveraging cost advantages and robust supply chains. The Indian government’s focus on pharmaceutical self-reliance, coupled with export incentives, further strengthens this sector.

• China:
  China is another significant API manufacturing hub, with several GMP-certified producers capable of synthesizing PAS at large scales. Chinese manufacturers often serve both domestic and export markets, with some emerging as specialized API suppliers for neglected diseases.

• European Union:
  Though less prominent for bulk PAS production, certain EU-based manufacturers focus on high-quality APIs with stringent regulatory standards. Companies here often target high-margin markets requiring rigorous quality and traceability.

2. Emerging Suppliers and Niche Producers

• South Korea and Southeast Asia:
  These regions increasingly contribute to global API supplies, emphasizing quality control and regulatory compliance. Such suppliers are poised to be future players in the Nydrazid API market.

---

Quality Assurance and Regulatory Compliance

Regulatory Standards:
Sourcing from WHO-GMP, USFDA, EMA, or PMDA-certified sources is critical for ensuring API quality. The quality of Nydrazid API directly influences clinical efficacy, safety profiles, and regulatory approval processes.

Validation and Certification:

• Good Manufacturing Practices (GMP)
• Certificate of Analysis (CoA)
• Certificates of Suitability (CEP) or Drug Master Files (DMF)
• Stability data and impurity profiles

Manufacturers with a proven track record adhering to these standards are preferred, especially in regulated markets.

---

Supply Chain Considerations

• Reliability and Capacity:
  Suppliers with proven track records, diversified production capacities, and contingency plans mitigate risk–especially vital given the ongoing global supply disruptions.

• Pricing and Contracting:
  Costs vary based on volume, supplier reputation, and quality certifications. Long-term supply agreements often ensure price stability and prioritized production.

• Logistics and Lead Times:
  Efficient logistics networks and fulfilled regulatory documentation expedite procurement and minimize delays.

• Geopolitical Risks:
  Political stability and export policies influence supplier reliability. Strategic diversification across regions reduces dependence on a single source.

---

Emerging Trends and Strategic Recommendations

• In-house Synthesis vs Outsourcing:
  Some large pharmaceutical firms prefer vertical integration, manufacturing PAS internally, ensuring quality and supply security.

• The Role of Contract Manufacturing Organizations (CMOs):
  Engaging trusted CMOs can optimize capacity utilization, reduce costs, and expedite market entry.

• Quality and Price Balance:
  Balancing API quality with cost is essential, especially for drugs used in developing countries where affordability is critical.

• Regulatory Harmonization:
  Working with suppliers familiar with global standards streamlines approval processes across regions.

---

Challenges in API Sourcing for Nydrazid

• Limited Number of Suppliers:
  The niche nature of PAS synthesis limits the supplier pool, which can lead to bottlenecks.

• Stringent Regulatory Requirements:
  Higher certification standards entail rigorous audits and documentation.

• Price Volatility:
  Fluctuations in raw material costs and geopolitical factors sometimes impact prices.

• Intellectual Property and Patent Landscape:
  Though Nydrazid is generic, potential patent litigations in certain jurisdictions could influence sourcing options.

---

Conclusion

The global API landscape for Nydrazid is characterized by prominent production hubs in India and China, supported by regional and niche suppliers. Ensuring high-quality, regulatory-compliant bulk APIs necessitates strategic partnerships with certified manufacturers, emphasizing quality assurance, supply chain resilience, and cost-effective procurement. Developing diversified sourcing strategies, fostering long-term contracts, and staying attuned to regulatory standards are crucial for sustained success in supplying Nydrazid.

---

Key Takeaways

• India and China dominate the bulk API production landscape for Nydrazid, offering cost-effective, high-quality options.
• Strict adherence to GMP standards and regulatory certifications is non-negotiable to ensure API quality.
• Supply chain risk mitigation involves diversifying supplier bases and engaging with reliable CMOs.
• Financial and geopolitical factors influence pricing and availability, requiring ongoing market monitoring.
• Strategic partnerships and long-term contracts are vital for consistent, compliant supply of Nydrazid API.

---

FAQs

1. What are the leading global manufacturers of Nydrazid API?
Major manufacturers include Indian firms like Sun Pharma, and Chinese providers with GMP certification. Specific company details depend on proprietary sourcing and licensing agreements.

2. How can companies verify the quality of Nydrazid API from suppliers?
By reviewing Certificates of Analysis (CoA), Certificates of Suitability (CEP), GMP certifications, and conducting independent testing if necessary.

3. What are the typical lead times for sourcing bulk Nydrazid API?
Lead times generally range from 4 to 12 weeks, depending on supplier location, order volume, regulatory documentation, and logistics.

4. Are there regional restrictions or import/export regulations affecting Nydrazid API sourcing?
Yes. Regulations vary by country. Import/export licenses, customs procedures, and tariffs can impact procurement strategies.

5. What trends are shaping the future of Nydrazid API supply?
Increased emphasis on quality, supply chain diversification, and regulatory harmonization drive sourcing strategies, alongside growth in generic manufacturing capacity in emerging markets.

---

References
[1] World Health Organization. Global Tuberculosis Report 2022.